Expression of tumor suppressive microRNA-34a is associated with a reduced risk of bladder cancer recurrence
-
Published Date:Feb 25 2015
-
Publisher's site:
-
Source:Int J Cancer. 137(5):1158-1166.
Details:
-
Personal Authors:
-
Keywords:
-
Pubmed ID:25556547
-
Pubmed Central ID:PMC4485975
-
Description:Bladder cancer is the fourth most common cancer among men in the United States and more than half of patients experience recurrences within 5 years after initial diagnosis. Additional clinically informative and actionable biomarkers of the recurrent bladder cancer phenotypes are needed to improve screening and molecular therapeutic approaches for recurrence prevention. MicroRNA-34a (miR-34a) is a short noncoding regulatory RNA with tumor suppressive attributes. We leveraged our unique, large, population-based prognostic study of bladder cancer in New Hampshire, United States to evaluate miR-34a expression levels in individual tumor cells to assess prognostic value. We collected detailed exposure and medical history data, as well as tumor tissue specimens from bladder patients and followed them long-term for recurrence, progression and survival. Fluorescence-based in situ hybridization assays were performed on urothelial carcinoma tissue specimens (n = 229). A larger proportion of the nonmuscle invasive tumors had high levels of miR-34a within the carcinoma cells compared to those tumors that were muscle invasive. Patients with high miR-34a levels in their baseline nonmuscle invasive tumors experienced lower risks of recurrence (adjusted hazard ratio 0.57, 95% confidence interval 0.34-0.93). Consistent with these observations, we demonstrated a functional tumor suppressive role for miR-34a in cultured urothelial cells, including reduced matrigel invasion and growth in soft agar. Our results highlight the need for further clinical studies of miR-34a as a guide for recurrence screening and as a possible candidate therapeutic target in the bladder.
-
Document Type:
-
Collection(s):
-
Funding:5P42ES05947/ES/NIEHS NIH HHS/United States
CA078609/CA/NCI NIH HHS/United States
CA099500/CA/NCI NIH HHS/United States
CA102327/CA/NCI NIH HHS/United States
CA121382/CA/NCI NIH HHS/United States
CA141017/CA/NCI NIH HHS/United States
CA182659/CA/NCI NIH HHS/United States
CA82354/CA/NCI NIH HHS/United States
ES00002/ES/NIEHS NIH HHS/United States
ES07373/ES/NIEHS NIH HHS/United States
GM103506/GM/NIGMS NIH HHS/United States
GM103534/GM/NIGMS NIH HHS/United States
K07 CA102327/CA/NCI NIH HHS/United States
K07CA102327/CA/NCI NIH HHS/United States
LM009012/LM/NLM NIH HHS/United States
P20 GM103534/GM/NIGMS NIH HHS/United States
P20 RR018787/RR/NCRR NIH HHS/United States
P20 RR024475/RR/NCRR NIH HHS/United States
P30 CA023108/CA/NCI NIH HHS/United States
P30 ES000002/ES/NIEHS NIH HHS/United States
P42 ES005947/ES/NIEHS NIH HHS/United States
P42 ES007373/ES/NIEHS NIH HHS/United States
R01 CA078609/CA/NCI NIH HHS/United States
R01 CA082354/CA/NCI NIH HHS/United States
R01 LM009012/LM/NLM NIH HHS/United States
R03 CA099500/CA/NCI NIH HHS/United States
R03 CA121382/CA/NCI NIH HHS/United States
R21 CA141017/CA/NCI NIH HHS/United States
R21 CA182659/CA/NCI NIH HHS/United States
RR018787/RR/NCRR NIH HHS/United States
RR024475/RR/NCRR NIH HHS/United States
RR028309/RR/NCRR NIH HHS/United States
U58/DP000798/DP/NCCDPHP CDC HHS/United States
-
Supporting Files:
image/gif image/jpeg image/gif image/jpeg image/gif image/jpeg image/gif image/jpeg image/gif image/jpeg image/tiff image/gif image/jpeg image/tiff application/vnd.openxmlformats-officedocument.wordprocessingml.document application/octet-stream image/gif image/jpeg image/gif image/jpeg
No Related Documents.
You May Also Like: